Department of Pharmacology, Christian Medical College and Hospital, Ludhiana, India.
Basic Clin Pharmacol Toxicol. 2012 Mar;110(3):227-30. doi: 10.1111/j.1742-7843.2011.00788.x. Epub 2011 Sep 28.
The objective of this study is to evaluate the effects of bupropion as an add-on therapy to selective serotonin reuptake inhibitor (SSRI) on patients of major depressive disorder with partial response. This prospective, randomized, controlled and single-blind study was conducted in sixty patients suffering from major depressive disorder as per Diagnostic and Statistical Manual (DSM)-IV TR criteria, who were having Hamilton depression rating scale (HDRS) score ≥16 after 4 weeks of treatment with SSRIs. Group A received SSRI plus placebo and group B received SSRI plus bupropion. Evaluation was performed based on changes in HDRS score, Montgomery and Asberg depression rating scale (MADRS), Amritsar depressive inventory (ADI) and spontaneously reported adverse effects. There was a significant decrease in the HDRS, MADRS and ADI scores as compared to baseline in both groups. However, the mean decrease in depression score was more in group B than in group A. The percentage decrease of remitters was also significantly more in group B (60% as per HDRS score and 63% as per MADRS score), as compared to group A (24% as per HDRS score and 27% as per MADRS score) (p < 0.05), at the end of treatment. In conclusion, bupropion add-on can act as augmenting agent in patients of depression with partial response to SSRIs.
本研究旨在评估安非他酮作为增效剂联合选择性 5-羟色胺再摄取抑制剂（SSRI）治疗对伴有部分反应的重性抑郁障碍患者的疗效。这是一项前瞻性、随机、对照和单盲研究，共纳入 60 名符合 DSM-IV-TR 标准的重性抑郁障碍患者，这些患者在接受 SSRI 治疗 4 周后，汉密尔顿抑郁量表（HDRS）评分≥16。A 组接受 SSRI 联合安慰剂，B 组接受 SSRI 联合安非他酮。根据 HDRS 评分、蒙哥马利-阿斯伯格抑郁评定量表（MADRS）、阿姆利则抑郁量表（ADI）和自发报告的不良反应的变化来进行评估。与基线相比，两组的 HDRS、MADRS 和 ADI 评分均显著下降。然而，B 组的抑郁评分平均下降幅度大于 A 组。治疗结束时，B 组的缓解率（根据 HDRS 评分和 MADRS 评分，分别为 60%和 63%）也明显高于 A 组（分别为 24%和 27%）（p<0.05）。结论：安非他酮作为增效剂可用于治疗对 SSRI 反应部分缓解的抑郁患者。
